Table of Content

1. Introduction


2. Research & Methodology


3. Executive Summary


4. Market Dynamics

4.1 Growth Drivers
4.2 Challenges


5. Non-Small Cell Lung Cancer Treatment (NSCLC) Market


6. Market Share Analysis – Non-Small Cell Lung Cancer Treatment (NSCLC)

6.1 By Histology Type
6.2 By Treatment Type
6.3 By Drug Class
6.4 By End User
6.5 By Region


7. Histology Type – Non-Small Cell Lung Cancer Treatment (NSCLC) Market

7.1 Adenocarcinoma
7.2 Squamous Cell Carcinoma
7.3 Large Cell Carcinoma


8. Treatment Type – Non-Small Cell Lung Cancer Treatment (NSCLC) Market

8.1 Chemotherapy
8.2 Immunotherapy
8.3 Radiation Therapy
8.4 Surgery
8.5 Targeted Therapy Drugs


9. Drug Class – Non-Small Cell Lung Cancer Treatment (NSCLC) Market

9.1 Angiogenesis Inhibitor
9.2 Epidermal Growth Factor Receptor Blocker
9.3 Kinase Inhibitor
9.4 Microtubule Stabilizer
9.5 Folate Antimetabolites
9.6 PD-1/ PD-L1 Inhibitor


10. End User – Non-Small Cell Lung Cancer Treatment (NSCLC) Market

10.1 General Medical & Surgical Hospitals
10.2 Specialty Hospitals
10.3 Clinics
10.4 Others


11. Region – Non-Small Cell Lung Cancer Treatment (NSCLC) Market

11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Rest of The World


12. Porters Five Forces

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes


13. Key Players

13.1 AbbVie Inc.

13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue

13.2 Astellas Pharma

13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue

13.3 AstraZeneca

13.3.1 Overview
13.3.2 Recent Development
13.3.3 Revenue

13.4 Avid Bioservices Inc.

13.4.1 Overview
13.4.2 Recent Development
13.4.3 Revenue

13.5 Bayer Healthcare

13.5.1 Overview
13.5.2 Recent Development
13.5.3 Revenue

13.6 Biogen Inc.

13.6.1 Overview
13.6.2 Recent Development
13.6.3 Revenue

13.7 Blueprint Medicines Corp

13.7.1 Overview
13.7.2 Recent Development
13.7.3 Revenue

13.8 Eli Lilly and Company

13.8.1 Overview
13.8.2 Recent Development
13.8.3 Revenue

13.9 Merck & co Inc.

13.9.1 Overview
13.9.2 Recent Development
13.9.3 Revenue

13.10 Novartis

13.10.1 Overview
13.10.2 Recent Development
13.10.3 Revenue

13.11 Pfizer Inc.

13.11.1 Overview
13.11.2 Recent Development
13.11.3 Revenue



List of Figures

Figure-01: Global – Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2016 – 2021
Figure-02: Global – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Billion US$), 2022 – 2027
Figure-03: Histology Type – Adenocarcinoma Market (Million US$), 2016 – 2021
Figure-04: Histology Type – Forecast for Adenocarcinoma Market (Million US$), 2022 – 2027
Figure-05: Histology Type – Squamous Cell Carcinoma Market (Million US$), 2016 – 2021
Figure-06: Histology Type – Forecast for Squamous Cell Carcinoma Market (Million US$), 2022 – 2027
Figure-07: Histology Type – Large Cell Carcinoma Market (Million US$), 2016 – 2021
Figure-08: Histology Type – Forecast for Large Cell Carcinoma Market (Million US$), 2022 – 2027
Figure-09: Treatment Type – Chemotherapy Market (Million US$), 2016 – 2021
Figure-10: Treatment Type – Forecast for Chemotherapy Market (Million US$), 2022 – 2027
Figure-11: Treatment Type – Immunotherapy Market (Million US$), 2016 – 2021
Figure-12: Treatment Type – Forecast for Immunotherapy Market (Million US$), 2022 – 2027
Figure-13: Treatment Type – Radiation Therapy Market (Million US$), 2016 – 2021
Figure-14: Treatment Type – Forecast for Radiation Therapy Market (Million US$), 2022 – 2027
Figure-15: Treatment Type – Surgery Market (Million US$), 2016 – 2021
Figure-16: Treatment Type – Forecast for Surgery Market (Million US$), 2022 – 2027
Figure-17: Treatment Type – Targeted Therapy Drugs Market (Million US$), 2016 – 2021
Figure-18: Treatment Type – Forecast for Targeted Therapy Drugs Market (Million US$), 2022 – 2027
Figure-19: Drug Class – Angiogenesis Inhibitor Market (Million US$), 2016 – 2021
Figure-20: Drug Class – Forecast for Angiogenesis Inhibitor Market (Million US$), 2022 – 2027
Figure-21: Drug Class – Epidermal Growth Factor Receptor Blocker Market (Million US$), 2016 – 2021
Figure-22: Drug Class – Forecast for Epidermal Growth Factor Receptor Blocker Market (Million US$), 2022 – 2027
Figure-23: Drug Class – Kinase Inhibitor Market (Million US$), 2016 – 2021
Figure-24: Drug Class – Forecast for Kinase Inhibitor Market (Million US$), 2022 – 2027
Figure-25: Drug Class – Microtubule Stabilizer Market (Million US$), 2016 – 2021
Figure-26: Drug Class – Forecast for Microtubule Stabilizer Market (Million US$), 2022 – 2027
Figure-27: Drug Class – Folate Antimetabolites Market (Million US$), 2016 – 2021
Figure-28: Drug Class – Forecast for Folate Antimetabolites Market (Million US$), 2022 – 2027
Figure-29: Drug Class – PD-1/ PD-L1 Inhibitor Market (Million US$), 2016 – 2021
Figure-30: Drug Class – Forecast for PD-1/ PD-L1 Inhibitor Market (Million US$), 2022 – 2027
Figure-31: End User – General Medical & Surgical Hospitals Market (Million US$), 2016 – 2021
Figure-32: End User – Forecast for General Medical & Surgical Hospitals Market (Million US$), 2022 – 2027
Figure-33: End User – Specialty Hospitals Market (Million US$), 2016 – 2021
Figure-34: End User – Forecast for Specialty Hospitals Market (Million US$), 2022 – 2027
Figure-35: End User – Clinics Market (Million US$), 2016 – 2021
Figure-36: End User – Forecast for Clinics Market (Million US$), 2022 – 2027
Figure-37: End User – Others Market (Million US$), 2016 – 2021
Figure-38: End User – Forecast for Others Market (Million US$), 2022 – 2027
Figure-39: North America – Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 – 2021
Figure-40: North America – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 – 2027
Figure-41: Europe – Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 – 2021
Figure-42: Europe – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 – 2027
Figure-43: Asia-Pacific – Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 – 2021
Figure-44: Asia-Pacific – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 – 2027
Figure-45: Rest of the World – Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2016 – 2021
Figure-46: Rest of the World – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market (Million US$), 2022 – 2027
Figure-47: AbbVie Inc. – Global Revenue (Million US$), 2016 – 2021
Figure-48: AbbVie Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-49: Astellas Pharma – Global Revenue (Million US$), 2016 – 2021
Figure-50: Astellas Pharma – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-51: AstraZeneca – Global Revenue (Million US$), 2016 – 2021
Figure-52: AstraZeneca – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-53: Avid Bioservices Inc. – Global Revenue (Million US$), 2016 – 2021
Figure-54: Avid Bioservices Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-55: Bayer Healthcare – Global Revenue (Million US$), 2016 – 2021
Figure-56: Bayer Healthcare – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-57: Biogen Inc. – Global Revenue (Million US$), 2016 – 2021
Figure-58: Biogen Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-59: Blueprint Medicines Corp – Global Revenue (Million US$), 2016 – 2021
Figure-60: Blueprint Medicines Corp – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-61: Eli Lilly and Company – Global Revenue (Million US$), 2016 – 2021
Figure-62: Eli Lilly and Company – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-63: Merck & co Inc. – Global Revenue (Million US$), 2016 – 2021
Figure-64: Merck & co Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-65: Novartis – Global Revenue (Million US$), 2016 – 2021
Figure-66: Novartis – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-67: Pfizer Inc. – Global Revenue (Million US$), 2016 – 2021
Figure-68: Pfizer Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027

List of Tables

Table-01: Global – Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Histology Type (Percent), 2016 – 2021
Table-02: Global – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Histology Type (Percent), 2022 – 2027
Table-03: Global – Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment Type (Percent), 2016 – 2021
Table-04: Global – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Treatment Type (Percent), 2022 – 2027
Table-05: Global – Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2016 – 2021
Table-06: Global – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Drug Class (Percent), 2022 – 2027
Table-07: Global – Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2016 – 2021
Table-08: Global – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by End-User (Percent), 2022 – 2027
Table-09: Global – Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (Percent), 2016 – 2021
Table-10: Global – Forecast for Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Region (Percent), 2022 – 2027